Archives of Dermatological Research

, Volume 302, Issue 3, pp 155–168 | Cite as

The skin pathergy test: innately useful?

  • Alexandra Varol
  • Oliver Seifert
  • Chris D. Anderson
Mini Review
First Online:
Received:
Revised:
Accepted:

Abstract

Pathergy is the term used to describe hyper-reactivity of the skin that occurs in response to minimal trauma. A positive skin pathergy test (SPT), characterised by erythematous induration at the site of the needle stick with a small pustule containing sterile pus at its centre, is among the criteria required for a diagnosis of Behçet’s disease (BD) and in certain population has been shown to be highly specific for this condition. Problems with standardising the induction manoeuvre for the SPT as well as the method of assessment of the response have limited the usefulness of the SPT in the clinical setting. Extensive investigation into histopathological and immunological aspects of pathergy has led to a number of hypotheses relating to the aetiology of the skin pathergy reaction and the disease itself, but the cause is considered to be unknown. Pathergy lesions, the development of new skin lesions or the aggravation of existing ones following trivial trauma, are also reported in pyoderma gangrenosum and has been noted in other neutrophilic dermatoses such as Sweet’s syndrome. The response of such patient groups to the systematic application of the SPT has not been described. We propose that a new way of considering the pathergy reaction is to see it as an aberration of the skin’s innate reactivity from a homeostatic reactive mode closely coupled to tissue healing to an abnormal destructive/inflammatory mode. Our understanding of BD and other similar conditions would profit by more detailed mechanistic knowledge of skin homeostasis to minimal trauma in both health and disease through a more structured and systematic use of the SPT.

Keywords

Pathergy Behçet’s disease Skin pathergy test Pyoderma gangrenosum Innate immunity 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Akman A, Sallakci N, Coskun M, Bacanli A, Yavuzer U, Alpsoy E, Yegin O (2006) TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behcet’s disease. Br J Dermatol 155:350–356PubMedGoogle Scholar
  2. 2.
    Akmaz O, Erel A, Gurer MA (2000) Comparison of histopathologic and clinical evaluations of pathergy test in Behcet’s disease. Int J Dermatol 39:121–125PubMedGoogle Scholar
  3. 3.
    Aksu K, Kitapcioglu G, Keser G, Berdeli A, Karabulut G, Kobak S, Ozmen M, Inal V, Kabasakal Y, Oksel F, Kocanaogullari H, Doganavsargil E (2008) FcgammaRIIa, IIIa and IIIb gene polymorphisms in Behcet’s disease: do they have any clinical implications? Clin Exp Rheumatol 26:S77–S83PubMedGoogle Scholar
  4. 4.
    al-Dalaan AN, al Balaa SR, el Ramahi K, al-Kawi Z, Bohlega S, Bahabri S, al Janadi MA (1994) Behcet’s disease in Saudi Arabia. J Rheumatol 21:658–661PubMedGoogle Scholar
  5. 5.
    Al-Rawi ZS, Sharquie KE, Khalifa SJ, Al-Hadithi FM, Munir JJ (1986) Behcet’s disease in Iraqi patients. Ann Rheum Dis 45:987–990PubMedGoogle Scholar
  6. 6.
    Alayli G, Aydin F, Coban AY, Sullu Y, Canturk F, Bek Y, Durupinar B, Canturk T (2007) T helper 1 type cytokines polymorphisms: association with susceptibility to Behcet’s disease. Clin Rheumatol 26:1299–1305PubMedGoogle Scholar
  7. 7.
    Alpsoy E, Donmez L, Onder M, Gunasti S, Usta A, Karincaoglu Y, Kandi B, Buyukkara S, Keseroglu O, Uzun S, Tursen U, Seyhan M, Akman A (2007) Clinical features and natural course of Behcet’s disease in 661 cases: a multicentre study. Br J Dermatol 157:901–906PubMedGoogle Scholar
  8. 8.
    Altenburg A, Papoutsis N, Orawa H, Martus P, Krause L, Zouboulis CC (2006) Epidemiology and clinical manifestations of Adamantiades–Behcet disease in Germany—current pathogenetic concepts and therapeutic possibilities. J Dtsch Dermatol Ges 4:49–64 (quiz 65–46)PubMedGoogle Scholar
  9. 9.
    Anderson C, Andersson T, Wardell K (1994) Changes in skin circulation after insertion of a microdialysis probe visualized by laser Doppler perfusion imaging. J Invest Dermatol 102:807–811PubMedGoogle Scholar
  10. 10.
    Askari A, Al-Aboosi M, Sawalha A (2000) Evaluation of pathergy test in North Jordan. Clin Rheumatol 19:249–251PubMedGoogle Scholar
  11. 11.
    Ates A, Kinikli G, Duzgun N, Duman M (2006) Lack of association of tumor necrosis factor-alpha gene polymorphisms with disease susceptibility and severity in Behcet’s disease. Rheumatol Int 26:348–353PubMedGoogle Scholar
  12. 12.
    Bakhshi S, Sethuraman G, Singh MK, Arya LS (2005) Atypical pyoderma gangrenosum as a manifestation of childhood acute lymphoblastic leukemia. Pediatr Dermatol 22:543–545PubMedGoogle Scholar
  13. 13.
    Barton GM (2008) A calculated response: control of inflammation by the innate immune system. J Clin Invest 118:413–420PubMedGoogle Scholar
  14. 14.
    Behcet H (1940) Some observations on the clinical picture of the so-called triple symptom complex. Dermatologica 81:73Google Scholar
  15. 15.
    Belzunegui J, Lopez L, Paniagua I, Intxausti JJ, Maiz O (2008) Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behcet’s disease. Clin Exp Rheumatol 26:S133–S134PubMedGoogle Scholar
  16. 16.
    Bhisitkul RB, Foster CS (1996) Diagnosis and ophthalmological features of Behcet’s disease. Int Ophthalmol Clin 36:127–134PubMedGoogle Scholar
  17. 17.
    Blobner F (1937) Zur rezidivierenden Hypopyon-Iritis. Z Augenheilk 91:129Google Scholar
  18. 18.
    Brennecke A (1996) Peristomal pyoderma gangrenosum: review and case study. Medsurg Nurs 5:195–198, 217Google Scholar
  19. 19.
    Budak-Alpdogan T, Demircay Alpdogan O, Direskeneli H, Ergun T, Ozturk A, Gunay A, Yavuz S, Uskent N, Akoglu T (1998) Skin hyperreactivity of Behcet’s patients (pathergy reaction) is also positive in interferon alpha-treated chronic myeloid leukaemia patients, indicating similarly altered neutrophil functions in both disorders. Br J Rheumatol 37:1148–1151PubMedGoogle Scholar
  20. 20.
    Callen JP (1998) Pyoderma gangrenosum. Lancet 351:581–585PubMedGoogle Scholar
  21. 21.
    Callen JP, Jackson JM (2007) Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 33:787–802 (vi)Google Scholar
  22. 22.
    Callen JP, Taylor WB (1978) Pyoderma gangrenosum—a literature review. Cutis 21:61–64PubMedGoogle Scholar
  23. 23.
    Chajek T, Fainaru M (1980) Behcet’s disease. In: Parker CW (ed) Clinical immunology. Philadelphia, pp 667Google Scholar
  24. 24.
    Chang HK, Cheon KS (2002) The clinical significance of a pathergy reaction in patients with Behcet’s disease. J Korean Med Sci 17:371–374PubMedGoogle Scholar
  25. 25.
    Conrad C, Trueb RM (2005) Pyoderma gangrenosum. J Dtsch Dermatol Ges 3:334–342PubMedGoogle Scholar
  26. 26.
    Coskun M, Bacanli A, Sallakci N, Alpsoy E, Yavuzer U, Yegin O (2005) Specific interleukin-1 gene polymorphisms in Turkish patients with Behcet’s disease. Exp Dermatol 14:124–129PubMedGoogle Scholar
  27. 27.
    Davatchi F, Shahram F, Akbariam M, Gharibdoost F, Nadji A, Chams C (1993) Accuracy of existing diagnostic criteria for Behcet’s disease. In: Wechsler B, Godeau P (eds) Behcet’s disease. Elsevier, Amsterdam, pp 225–228Google Scholar
  28. 28.
    Davies PG, Fordham JN, Kirwan JR, Barnes CG, Dinning WJ (1984) The pathergy test and Behcet’s syndrome in Britain. Ann Rheum Dis 43:70–73PubMedGoogle Scholar
  29. 29.
    Deuter CM, Kotter I, Wallace GR, Murray PI, Stubiger N, Zierhut M (2008) Behcet’s disease: ocular effects and treatment. Prog Retin Eye Res 27:111–136PubMedGoogle Scholar
  30. 30.
    Dilsen N, Konice M, Aral O (1985) Our diagnostic criteria of Behcets disease: an overview. Recent Advances in Behcets disease, Services RSoM, LondonGoogle Scholar
  31. 31.
    Dilsen N, Konice M, Aral O, Aykut S (1986) Standardization and evaluation of the skin pathergy test in Behcet’s disease and controls. In: Lehner T, Barnes C (eds) Recent advances in Behcet’s disease. Royal Society of Medicine Services, London, pp 177–180Google Scholar
  32. 32.
    Dilsen N, Konice M, Aral O, Ocal L, Inanc M, Gul A (1993) Comparative study of the skin pathergy test with blunt and sharp needles in Behcet’s disease: confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis 52:823–825PubMedGoogle Scholar
  33. 33.
    Do JE, Kwon SY, Park S, Lee ES (2008) Effects of vitamin D on expression of Toll-like receptors of monocytes from patients with Behcet’s disease. Rheumatology (Oxford) 47:840–848Google Scholar
  34. 34.
    Dundar SV, Gencalp U, Simsek H (1985) Familial cases of Behcet’s disease. Br J Dermatol 113:319–321PubMedGoogle Scholar
  35. 35.
    Dursun A, Durakbasi-Dursun H, Dursun R, Baris S, Akduman L (2009) Angiotensin-converting enzyme gene and endothelial nitric oxide synthase gene polymorphisms in Behçet’s disease with or without ocular involvement. Inflamm Res 58(7):401–405Google Scholar
  36. 36.
    Dwarakanath AD, Yu LG, Brookes C, Pryce D, Rhodes JM (1995) ‘Sticky’ neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut 37:585–588PubMedGoogle Scholar
  37. 37.
    Efthimiou J, Johnston C, Spiro SG, Turner-Warwick M (1986) Pulmonary disease in Behcet’s syndrome. Q J Med 58:259–280PubMedGoogle Scholar
  38. 38.
    Ek L, Hedfors E (1993) Behcet’s disease: a review and a report of 12 cases from Sweden. Acta Derm Venereol 73:251–254PubMedGoogle Scholar
  39. 39.
    Ergun T, Gurbuz O, Harvell J, Jorizzo J, White W (1998) The histopathology of pathergy: a chronologic study of skin hyperreactivity in Behcet’s disease. Int J Dermatol 37:929–933PubMedGoogle Scholar
  40. 40.
    Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, Aractingi S, Khosrotehrani K (2008) Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore) 87:281–293Google Scholar
  41. 41.
    Fei Y, Webb R, Cobb BL, Direskeneli H, Saruhan-Direskeneli G, Sawalha AH (2009) Identification of novel genetic susceptibility loci for Behcet’s disease using a genome-wide association study. Arthritis Res Ther 11:R66PubMedGoogle Scholar
  42. 42.
    Ferraz MB, Walter SD, Heymann R, Atra E (1995) Sensitivity and specificity of different diagnostic criteria for Behcet’s disease according to the latent class approach. Br J Rheumatol 34:932–935PubMedGoogle Scholar
  43. 43.
    Fox LP, Geyer AS, Husain S, Grossman ME (2006) Bullous pyoderma gangrenosum as the presenting sign of fatal acute myelogenous leukemia. Leuk Lymphoma 47:147–150PubMedGoogle Scholar
  44. 44.
    Friedman-Birnbaum R, Bergman R, Aizen E (1990) Sensitivity and specificity of pathergy test results in Israeli patients with Behcet’s disease. Cutis 45:261–264PubMedGoogle Scholar
  45. 45.
    Fritsch P (1998) Papulöse lichenoide Dermatosen. In: Fritsch P (ed) Dermatologie und Venerologie. Lehrbuch und Atlas. Springer, Berlin, Heidelberg, New York, pp 355Google Scholar
  46. 46.
    Gilhar A, Winterstein G, Turani H, Landau J, Etzioni A (1989) Skin hyperreactivity response (pathergy) in Behcet’s disease. J Am Acad Dermatol 21:547–552PubMedGoogle Scholar
  47. 47.
    Grob JJ, Mege JL, Follana J, Legre R, Andrac L, Bonerandi JJ (1990) Skin necrosis after injection of aminosides. Arthus reaction, local toxicity, thrombotic process or pathergy? Dermatologica 180:258–262PubMedGoogle Scholar
  48. 48.
    Gul A (2007) Standard and novel therapeutic approaches to Behcet’s disease. Drugs 67:2013–2022PubMedGoogle Scholar
  49. 49.
    Gul A, Esin S, Dilsen N, Konice M, Wigzell H, Biberfeld P (1995) Immunohistology of skin pathergy reaction in Behcet’s disease. Br J Dermatol 132:901–907PubMedGoogle Scholar
  50. 50.
    Gunesacar R, Erken E, Bozkurt B, Ozer HT, Dinkci S, Erken EG, Ozbalkan Z (2007) Analysis of CD28 and CTLA-4 gene polymorphisms in Turkish patients with Behcet’s disease. Int J Immunogenet 34:45–49PubMedGoogle Scholar
  51. 51.
    Gurler A, Boyvat A, Tursen U (1997) Clinical manifestations of Behcet’s disease: an analysis of 2147 patients. Yonsei Med J 38:423–427PubMedGoogle Scholar
  52. 52.
    Haim S, Sobel JD, Friedman-Birnbaum R, Lichtig C (1976) Histological and direct immunofluorescence study of cutaneous hyperreactivity in Behcet’s disease. Br J Dermatol 95:631–636PubMedGoogle Scholar
  53. 53.
    Herreman G, Beaufils H, Godeau P, Cassou B, Wechsler B, Boujeau J, Chomette G (1982) Behcet’s syndrome and renal involvement: a histological and immunofluorescent study of eleven renal biopsies. Am J Med Sci 284:10–17PubMedGoogle Scholar
  54. 54.
    Hombal S, Ahmed A (1986) Behcet’s disease. In: Thiers B, Dobson R (eds) Pathogenesis of skin disease. Churchill Livingstone, New York, pp 257–265Google Scholar
  55. 55.
    ISGfBD (1990) Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet 335:1078–1080Google Scholar
  56. 56.
    Jacobson S, Martin DB, Deng A, Cooper JZ (2008) Pyoderma gangrenosum following tattoo placement in a patient with acute myelogenous leukemia. J Dermatolog Treat 19:58–60PubMedGoogle Scholar
  57. 57.
    James DG, Thomson A (1982) Recognition of the diverse cardiovascular manifestation in Behcet’s disease. Am Heart J 103:457–458PubMedGoogle Scholar
  58. 58.
    Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestwich GD, Mascarenhas MM, Garg HG, Quinn DA, Homer RJ, Goldstein DR, Bucala R, Lee PJ, Medzhitov R, Noble PW (2005) Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 11:1173–1179PubMedGoogle Scholar
  59. 59.
    Jorizzo JL (1999) Behcet’s disease. In: Freedberg IM, Eisen A, Wolff K, Austin KF, Goldsmith LA, Katz SI, Fitzpatrick TB (eds) Fitzpatrick’s dermatology in general medicine. McGraw Hill, New York, pp 1836–1840Google Scholar
  60. 60.
    Jorizzo JL, Hudson RD, Schmalstieg FC, Daniels JC, Apisarnthanarax P, Henry JC, Gonzalez EB, Ichikawa Y, Cavallo T (1984) Behcet’s syndrome: immune regulation, circulating immune complexes, neutrophil migration, and colchicine therapy. J Am Acad Dermatol 10:205–214PubMedGoogle Scholar
  61. 61.
    Jorizzo JL, Solomon AR, Cavallo T (1985) Behcet’s syndrome: immunopathologic and histopathologic assessment of pathergy lesions is useful in diagnosis and follow-up. Arch Pathol Lab Med 109:747–751PubMedGoogle Scholar
  62. 62.
    Kamoun M, Chelbi H, Houman MH, Lacheb J, Hamzaoui K (2007) Tumor necrosis factor gene polymorphisms in Tunisian patients with Behcet’s disease. Hum Immunol 68:201–205PubMedGoogle Scholar
  63. 63.
    Katzenellenbogen I, Feuerman EJ (1965) Data on Behcet’s disease (significance of the specific skin hyperreactivity and of the Behcetin reaction). Hautarzt 16:13–18PubMedGoogle Scholar
  64. 64.
    Kaya TI, Tursen U, Ikizoglu G (2008) Large genital ulcers in a patient with Behcet’s disease associated with imiquimod cream treatment for external genital warts. Clin Exp Dermatol 33:783–784PubMedGoogle Scholar
  65. 65.
    Kitagawa N, Ikeda M, Kodama H (1996) Acute form of pyoderma gangrenosum induced by traumatic injury. J Dermatol 23:116–119PubMedGoogle Scholar
  66. 66.
    Krause I, Molad Y, Mitrani M, Weinberger A (2000) Pathergy reaction in Behcet’s disease: lack of correlation with mucocutaneous manifestations and systemic disease expression. Clin Exp Rheumatol 18:71–74PubMedGoogle Scholar
  67. 67.
    Krause L, Kohler AK, Altenburg A, Papoutsis N, Zouboulis CC, Pleyer U, Stroux A, Foerster MH (2009) Ocular involvement is associated with HLA-B51 in Adamantiades–Behcet’s disease. Eye 23:1182–1186PubMedGoogle Scholar
  68. 68.
    Krauze E, Brzezinska-Wcislo L, Kaminska-Winciorek G, Wygledowska-Kania M, Sygula E (2005) Pyoderma gangrenosum coexisting with acute myelogenous leukaemia. J Eur Acad Dermatol Venereol 19:589–592PubMedGoogle Scholar
  69. 69.
    Kuner N, Hartschuh W, Khan-Durani B (2003) Heinrich Kobner and the “isomorphic phenomenon”. History and review of the literature. Hautarzt 54:274–278PubMedGoogle Scholar
  70. 70.
    Leahy MJ, Enfield JG, Clancy NT, O’Doherty J, McNamara P, Nilsson GE (2007) Biophotonic methods in microcirculation imaging. Med Laser Appl 22:105–126Google Scholar
  71. 71.
    Lebwohl MG (1995) Atlas of the skin and systemic disease. Churchill Livingstone, New York, pp 65–77Google Scholar
  72. 72.
    Lee EB, Kim JY, Zhao J, Park MH, Song YW (2007) Haplotype association of IL-8 gene with Behcet’s disease. Tissue Antigens 69:128–132PubMedGoogle Scholar
  73. 73.
    Lee ES, Bang D, Lee S (1997) Dermatologic manifestation of Behcet’s disease. Yonsei Med J 38:380–389PubMedGoogle Scholar
  74. 74.
    Lehner T (1997) The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behcet’s disease. Int Rev Immunol 14:21–32PubMedGoogle Scholar
  75. 75.
    Lew W, Chang JY, Jung JY, Bang D (2008) Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Behcet’s disease. Br J Dermatol 158:505–511PubMedGoogle Scholar
  76. 76.
    Lewis T (1937) The nocifensor system of nerves and its reactions. Br Med J 194:431–435Google Scholar
  77. 77.
    Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2:612–619PubMedGoogle Scholar
  78. 78.
    Lichtig C, Haim S, Gilhar A, Hammel I, Ludatscher R (1981) Mast cells in Behcet’s disease: ultrastructural and histamine content studies. Dermatologica 162:167–174PubMedGoogle Scholar
  79. 79.
    Lindberg-Larsen R, Fogh K (2009) Traumatic pyoderma gangrenosum of the face: pathergy development after bike accident. Dermatology 218:272–274. doi: 10.1159/000182266 PubMedGoogle Scholar
  80. 80.
    Mariathasan S, Monack DM (2007) Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 7:31–40PubMedGoogle Scholar
  81. 81.
    McCalmont CS, Leshin B, White WL, Greiss FC Jr, Jorizzo JL (1991) Vulvar pyoderma gangrenosum. Int J Gynaecol Obstet 35:175–178PubMedGoogle Scholar
  82. 82.
    Menashi S, Tribout B, Dosquet C, Le Toumelin P, Piette JC, Wechsler B, Boffa MC (2008) Strong association between plasma thrombomodulin and pathergy test in Behcet disease. Ann Rheum Dis 67:892–893PubMedGoogle Scholar
  83. 83.
    Meylan E, Tschopp J, Karin M (2006) Intracellular pattern recognition receptors in the host response. Nature 442:39–44PubMedGoogle Scholar
  84. 84.
    Mizushima Y (1968) Chemotaxis and phagocytosis of leukocytes in Behcet’s disease: an overview. In: Lehner T, Barnes C (eds) Recent advances in Behcet’s disease. Royal Society of Medicine Services, London, pp 85–87Google Scholar
  85. 85.
    Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR (2006) Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock 26:430–437PubMedGoogle Scholar
  86. 86.
    Muftuoglu AU (1980) Symposium on the hematological and immunological aspects of Behcet’s disease: opening remarks. Haematologica 65:374–380PubMedGoogle Scholar
  87. 87.
    Nakao K, Isashiki Y, Sonoda S, Uchino E, Shimonagano Y, Sakamoto T (2007) Nitric oxide synthase and superoxide dismutase gene polymorphisms in Behcet disease. Arch Ophthalmol 125:246–251PubMedGoogle Scholar
  88. 88.
    Nara K, Kurokawa MS, Chiba S, Yoshikawa H, Tsukikawa S, Matsuda T, Suzuki N (2008) Involvement of innate immunity in the pathogenesis of intestinal Behcet’s disease. Clin Exp Immunol 152:245–251PubMedCrossRefGoogle Scholar
  89. 89.
    O’Doherty J, Henricson J, Anderson C, Leahy MJ, Nilsson GE, Sjoberg F (2007) Sub-epidermal imaging using polarized light spectroscopy for assessment of skin microcirculation. Skin Res Technol 13:472–484PubMedGoogle Scholar
  90. 90.
    O’Duffy JD (1978) Summary of international symposium on Behcet’s disease, Istanbul, September 29–30, 1977. J Rheumatol 5:229–233PubMedGoogle Scholar
  91. 91.
    O’Duffy JD (1981) Behcet’s disease. In: Kelly WB (ed) Textbook of rheumatology. WB Saunders, Philadelphia, pp 1197Google Scholar
  92. 92.
    Oksel F, Keser G, Ozmen M, Aksu K, Kitapcioglu G, Berdeli A, Doganavsargil E (2006) Endothelial nitric oxide synthase gene Glu298Asp polymorphism is associated with Behcet’s disease. Clin Exp Rheumatol 24:S79–S82PubMedGoogle Scholar
  93. 93.
    Olivieri I, Padula A, Leccese P, D’Angelo S, Giasi V (2009) Long-lasting remission of severe Behcet’s disease after the end of infliximab therapy. J Rheumatol 36:855PubMedGoogle Scholar
  94. 94.
    Ozarmagan G, Saylan T, Azizlerli G, Ovul C, Aksungur VL (1991) Re-evaluation of the pathergy test in Behcet’s disease. Acta Derm Venereol 71:75–76PubMedGoogle Scholar
  95. 95.
    Ozdemir M, Balevi S, Deniz F, Mevlitoglu I (2007) Pathergy reaction in different body areas in Behcet’s disease. Clin Exp Dermatol 32:85–87PubMedGoogle Scholar
  96. 96.
    Ozdemir M, Bodur S, Engin B, Baysal I (2008) Evaluation of application of multiple needle pricks on the pathergy reaction. Int J Dermatol 47:335–338PubMedGoogle Scholar
  97. 97.
    Parisi L, Terracciano ME, Valente GO, Calandriello E, Accorinti M, Spadaro M (1996) Pre-symptomatic neurological involvement in Behcet’s disease: the diagnostic role of magnetic transcranial stimulation. Electroencephalogr Clin Neurophysiol 101:42–47PubMedGoogle Scholar
  98. 98.
    Powell FC, Schroeter AL, Su WP, Perry HO (1985) Pyoderma gangrenosum: a review of 86 patients. Q J Med 55:173–186PubMedGoogle Scholar
  99. 99.
    Pugh M (ed) (2000) Stedman’s medical dictionary, 27th edn. Lippincott Williams and Wilkins, Baltimore, pp 1332Google Scholar
  100. 100.
    Rogers RS 3rd, Sams WM Jr, Shorter RG (1974) Lymphocytotoxicity in recurrent aphthous stomatitis. Lymphocytotoxicity for oral epithelial cells in recurrent aphthous stomatitis and Bechet syndrome. Arch Dermatol 109:361–363PubMedGoogle Scholar
  101. 101.
    Rolstad BS, Erwin-Toth PL (2004) Peristomal skin complications: prevention and management. Ostomy Wound Manage 50:68–77PubMedGoogle Scholar
  102. 102.
    Sagdic K, Ozer ZG, Saba D, Ture M, Cengiz M (1996) Venous lesions in Behcet’s disease. Eur J Vasc Endovasc Surg 11:437–440PubMedGoogle Scholar
  103. 103.
    Sahin S, Akoglu T, Direskeneli H, Sen LS, Lawrence R (1996) Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behcet’s disease. Ann Rheum Dis 55:128–133PubMedGoogle Scholar
  104. 104.
    Serhan CN (2007) Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25:101–137PubMedGoogle Scholar
  105. 105.
    Serhan CN, Savill J (2005) Resolution of inflammation: the beginning programs the end. Nat Immunol 6:1191–1197PubMedGoogle Scholar
  106. 106.
    Shimizu T, Ehrlich GE, Inaba G, Hayashi K (1979) Behcet disease (Behcet syndrome). Semin Arthritis Rheum 8:223–260PubMedGoogle Scholar
  107. 107.
    Singer AJ, Clark RA (1999) Cutaneous wound healing. N Engl J Med 341:738–746PubMedGoogle Scholar
  108. 108.
    Siva A, Altintas A, Saip S (2004) Behcet’s syndrome and the nervous system. Curr Opin Neurol 17:347–357PubMedGoogle Scholar
  109. 109.
    Sjogren F, Anderson C (2009) Sterile trauma to normal human dermis invariably induces IL1beta, IL6 and IL8 in an innate response to “danger”. Acta Derm Venereol 89:459–465PubMedGoogle Scholar
  110. 110.
    Sobel JD, Haim S, Shafrir A, Gellei B (1973) Cutaneous hyperreactivity in Behcet’s disease. Dermatologica 146:350–356PubMedGoogle Scholar
  111. 111.
    Sungnack L (1997) Dignostic criteria of Behcets disease: problems and suggestions. Yonsei Med J 38:365–369Google Scholar
  112. 112.
    Taylor KR, Yamasaki K, Radek KA, Di Nardo A, Goodarzi H, Golenbock D, Beutler B, Gallo RL (2007) Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem 282:18265–18275PubMedGoogle Scholar
  113. 113.
    Tunc R, Uluhan A, Melikoglu M, Ozyazgan Y, Ozdogan H, Yazici H (2001) A reassessment of the International Study Group criteria for the diagnosis (classification) of Behcet’s syndrome. Clin Exp Rheumatol 19:S45–S47PubMedGoogle Scholar
  114. 114.
    Tuzun Y, Yazici H, Pazarli H, Yalcin B, Yurdakul S, Muftuoglu A (1979) The usefulness of the nonspecific skin hyperreactivity (the pathergy test) in Behcet’s disease in Turkey. Acta Derm Venereol 59:77–79PubMedGoogle Scholar
  115. 115.
    Ueki H (2005) Koebner phenomenon in lupus erythematosus with special consideration of clinical findings. Autoimmun Rev 4:219–223PubMedGoogle Scholar
  116. 116.
    Wallace G (2009) Novel genetic analysis in Behcet’s disease. Arthritis Res Ther 11:123PubMedGoogle Scholar
  117. 117.
    Wallace GR, Kondeatis E, Vaughan RW, Verity DH, Chen Y, Fortune F, Madanat W, Kanawati CA, Graham EM, Stanford MR (2007) IL-10 genotype analysis in patients with Behcet’s disease. Hum Immunol 68:122–127PubMedGoogle Scholar
  118. 118.
    van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182:5836–5845PubMedGoogle Scholar
  119. 119.
    Wardell K, Naver HK, Nilsson GE, Wallin BG (1993) The cutaneous vascular axon reflex in humans characterized by laser Doppler perfusion imaging. J Physiol 460:185–199PubMedGoogle Scholar
  120. 120.
    Varol A (2005) A Minimally Invasive Human In vivo model of wound healing. Faculty of Medicine, University of NSW, AustraliaGoogle Scholar
  121. 121.
    Wiseman DH, Hunter HJ, Dennis M (2007) Bullous pyoderma gangrenosum in acute myeloid leukaemia. Eur J Haematol 79:91–92PubMedGoogle Scholar
  122. 122.
    Wolff K, Stingl G (2003) Pyoderma gangrenosum. In: Freedberg IM, Eisen A, Wolff K, Austin KF, Goldsmith LA, Katz SI, Fitzpatrick TB (eds) Fitzpatrick’s dermatology in general medicine. McGraw Hill, New York, pp 969–976Google Scholar
  123. 123.
    Wong RC, Ellis CN, Diaz LA (1984) Behcet’s disease. Int J Dermatol 23:25–32PubMedGoogle Scholar
  124. 124.
    Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI, Sharland AF, Chadban SJ (2007) TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 117:2847–2859PubMedGoogle Scholar
  125. 125.
    Yamasaki K, Muto J, Taylor KR, Cogen AL, Audish D, Bertin J, Grant EP, Coyle AJ, Misaghi A, Hoffman HM, Gallo RL (2009) NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem 284:12762–12771PubMedGoogle Scholar
  126. 126.
    Yayli S, Bahadir S, Alpay K, Cimsit G, Cobanoglu U, Tosun M (2005) Pyoderma gangrenosum in association with juvenile rheumatoid arthritis. J Dermatol 32:827–830PubMedGoogle Scholar
  127. 127.
    Yazici H, Chamberlain MA, Tuzun Y, Yurdakul S, Muftuoglu A (1984) A comparative study of the pathergy reaction among Turkish and British patients with Behcet’s disease. Ann Rheum Dis 43:74–75PubMedGoogle Scholar
  128. 128.
    Yazici H, Fresko I, Hamuryudan V, Mat C, Melikoglu M, Ozyazgan Y, Tuzun Y, Yurdakul S (1999) Behcet’s syndrome. The Cerrahpasa experience. Members of the Behcet’s Syndrome Research Centre. Adv Exp Med Biol 455:135–140PubMedGoogle Scholar
  129. 129.
    Yazici H, Tuzun Y, Pazarli H, Yalcin B, Yurdakul S, Muftuoglu A (1980) The combined use of HLA-B5 and the pathergy test as diagnostic markers of Behcet’s disease in Turkey. J Rheumatol 7:206–210PubMedGoogle Scholar
  130. 130.
    Yazici H, Tuzun Y, Tanman AB, Yurdakul S, Serdaroglu S, Pazarli H, Muftuoglu A (1985) Male patients with Behcet’s syndrome have stronger pathergy reactions. Clin Exp Rheumatol 3:137–141PubMedGoogle Scholar
  131. 131.
    Yazici H, Yurdakul S, Hamuryudan V (2001) Behcet disease. Curr Opin Rheumatol 13:18–22PubMedGoogle Scholar
  132. 132.
    Yco MS, Warnock GR, Cruickshank JC, Burnett JR (1988) Pyoderma gangrenosum involving the head and neck. Laryngoscope 98:765–768PubMedGoogle Scholar
  133. 133.
    Yurdakul S, Yazici H, Tuzun Y, Pazarli H, Yalcin B, Altac M, Ozyazgan Y, Tuzuner N, Muftuoglu A (1983) The arthritis of Behcet’s disease: a prospective study. Ann Rheum Dis 42:505–515PubMedGoogle Scholar
  134. 134.
    Zouboulis C (2008) Adamantiades - Behcet disease. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ (eds) Fitzpatrick’s dermatology in general medicine. McGraw Hill, New York, pp 1620–1626Google Scholar
  135. 135.
    Zouboulis CC, Keitel W (2002) A historical review of early descriptions of Adamantiades–Behcet’s disease. J Invest Dermatol 119:201–205PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Alexandra Varol
    • 1
  • Oliver Seifert
    • 2
  • Chris D. Anderson
    • 3
  1. 1.Department of DermatologyLiverpool HospitalSydneyAustralia
  2. 2.Division of DermatologyRyhov HospitalJönköpingSweden
  3. 3.Division of Dermatology, Department of Clinical and Experimental MedicineLinköping University HospitalLinköpingSweden

Personalised recommendations